Gamified Optimized Diabetes Management With Artificial Intelligence–Powered Rural Telehealth Intervention (GODART): Protocol for an Optimization Pilot and Feasibility Trial (Preprint)
Authors:
- Tapan MehtaTMTapan Mehta
- Tejossy JohnTJTejossy John
- Aseel El ZeinAZAseel El Zein
- Victoria FaughtVFVictoria Faught
- Tanjila NawshinTNTanjila Nawshin
- Tejaswini Subhash ChilkeTCTejaswini Subhash Chilke
- Caroline W CohenCCCaroline W Cohen
- Andrea CherringtonACAndrea Cherrington
- Mohanraj ThirumalaiMTMohanraj Thirumalai
Preprint
- 19 December 2024
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
BACKGROUND Type 2 diabetes mellitus (T2DM) is highly prevalent in the United States and represents a significant public health challenge. Telehealth interventions have shown promise for improving T2DM outcomes, but their effectiveness is often limited by disparities in digital literacy and access, especially in rural areas. To address this gap, we propose an innovative, individualized lifestyle modification intervention delivered via phone call to support glycemic control. OBJECTIVE This paper outlines the protocol for a pilot study designed to assess the feasibility and preliminary effectiveness of an artificial intelligence–assisted intervention for T2DM self-management in rural settings. METHODS The study uses the preparation phase of the MOST (Multiphase Optimization Strategy) framework to evaluate two components: (1) automated versus human health coaching and (2) fixed versus adapted gamified financial incentives, based on participants’ daily engagement with automated monitoring calls. We aim to enroll 88 adults with T2DM and hemoglobin A1c (HbA1c) levels between 6.5% and 11.5%. Participants receive daily interactive voice response calls tracking diet, physical activity, medication adherence, and blood glucose, and weekly coaching based on randomization. In the fixed-reward arm, participants earn US $0.60 per day; in the adaptive arm, rewards start at US $0.20 and increase weekly, with penalties for missed days. Primary outcomes include feasibility metrics and preliminary changes in HbA1c. Semistructured interviews will assess patient experience. RESULTS This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases. As of October 2025, we have enrolled and completed data collection for 88 participants. We expect to complete the feasibility analysis by December 2025. CONCLUSIONS This pilot and feasibility study evaluates a low-tech, artificial intelligence–assisted T2DM intervention designed to reduce digital barriers and inform a future MOST optimization trial. CLINICALTRIAL ClinicalTrials.gov NCT05344859; https://clinicaltrials.gov/study/NCT05344859 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/70271Keywords
All Related Versions
- Published version: JMIR Research Protocols, 14, e70271.
This publication has 63 references indexed in Scilit:
- From Innovation to Inclusion—Tackling Digital Equity Needs in Health CareJAMA Network Open, 2024
- Burden and management of type 2 diabetes in rural United StatesDiabetes/Metabolism Research and Reviews, 2020
- The Lifestyle Intervention for the Treatment of Diabetes study (LIFT Diabetes): Design and baseline characteristics for a randomized translational trial to improve control of cardiovascular disease risk factorsContemporary Clinical Trials, 2017
- Diabetes and Behavioral Learning Principles: Often Neglected yet Well-Known and Empirically Validated Means of Optimizing Diabetes Care BehaviorCurrent Diabetes Reports, 2015
- Factorial ExperimentsAmerican Journal of Preventive Medicine, 2014
- Optimization of remotely delivered intensive lifestyle treatment for obesity using the Multiphase Optimization Strategy: Opt-IN study protocolContemporary Clinical Trials, 2014
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- The Multiphase Optimization Strategy for Engineering Effective Tobacco Use InterventionsAnnals of Behavioral Medicine, 2010
- Sample size of 12 per group rule of thumb for a pilot studyPharmaceutical Statistics, 2005
- Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001JAMA, 2003